[Temporary Announcement] Aishelun: Announcement on using part of the raised funds to provide loans to wholly-owned subsidiaries to implement fundraising projects
Securities code: 920050 Securities abbreviation: Aishelun Announcement number: 2026-031
Jiangsu Aishelun Medical Technology Group Co., Ltd.
Announcement on using part of the raised funds to provide loans to wholly-owned subsidiaries to implement fundraising projects
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
Jiangsu Aishelun Medical Technology Group Co., Ltd. (hereinafter referred to as the "Company") held the 15th meeting of the Audit Committee of the second board of directors on March 27, 2026, and the 19th meeting of the second board of directors on March 27, 2026, and reviewed and approved the "About using part of the raised funds to provide loans to wholly-owned subsidiaries to "Proposal for Implementing Fund Raising Projects", which agreed that the company would use the funds raised from the public issuance of stocks to unspecified qualified investors to provide interest-free loans to the implementation entity of the raised capital investment project (hereinafter referred to as the "raising investment project"), namely the company's wholly-owned subsidiary Anhui Kepule Medical Technology Co., Ltd. (hereinafter referred to as "Kiple"), to implement the raising investment project. The relevant situation is now announced as follows:
1. Basic situation of raised funds
Jiangsu Aishelun Medical Technology Group Co., Ltd. (hereinafter referred to as the "Company") publicly issued shares to unspecified qualified investors and applied for listing on the Beijing Stock Exchange. The application was reviewed and approved by the Beijing Stock Exchange Listing Committee on October 24, 2025, and was approved by the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission" on December 10, 2025. "Approval for registration of Jiangsu Aishelun Medical Technology Group Co., Ltd.'s public issuance of stocks to unspecified qualified investors" (China Securities Regulatory Commission Permit [2025] No. 2754) issued by the company, the company's shares were listed on the Beijing Stock Exchange on January 21, 2026.
The company publicly issued 16,919,834 ordinary shares to unspecified qualified investors this time, with a par value of RMB 1.00 per share and an issuance price of RMB 15.98 per share. The total funds raised were RMB 270,378,947.32. After deducting the issuance expenses of RMB 30,202,199.50 (tax excluded), the company's net raised funds this time was RMB 240,176,747.82.
The raised funds were transferred to the company's designated account on January 14, 2026. The above-mentioned receipt of raised funds has been verified by Rongcheng Accounting Firm (Special General Partnership), which issued a "Capital Verification Report" (Rongcheng Yanzi [2026] No. 215Z0003).
After the raised funds arrive, the company opens a special account for raised funds to store the funds raised from the issuance of stocks to unspecified qualified investors, and has signed a "Three-Party Supervision Agreement for Raised Funds Special Account" with the commercial bank where the raised funds are deposited and Soochow Securities Co., Ltd. respectively.
2. The amount of raised funds to be invested in investment projects with raised funds
According to the "Prospectus" and "Announcement on Adjusting the Amount of Raised Funds to be Invested in Investment Projects with Raised Funds" (Announcement No.: 2026-014), the company's fundraising projects are as follows:
Unit: RMB 10,000
Original intended use of raised funds Planned investment after adjustment Serial number Project name Total investment amount
Amount of funds raised Amount of funds raised Kepler public health medical supplies
1 67,046.45 30,000.00 24,017.67 Industrial park construction project
Total 67,046.45 30,000.00 24,017.67
3. The use of part of the raised funds to provide loans to subsidiaries to implement fundraising projects
According to the plan for the use of the raised funds, the implementation entity of the raised investment project "Keple Public Health Medical Materials Industrial Park Construction Project" is the wholly-owned subsidiary Anhui Keple Medical Technology Co., Ltd. (hereinafter referred to as "Kaipule"). In order to ensure the smooth implementation of the raised investment project, the company plans to provide a loan of no more than 110 million yuan to Keple to implement the raised investment project.
The company will gradually issue loans to Kepler within the total loan limit in one go or in installments based on the construction arrangements and actual capital needs of the aforementioned investment projects. The loan is an interest-free loan with no specific repayment period. Kepler will repay it at a time based on its operating conditions. This loan can only be used for the implementation of investment projects and may not be used for other purposes; the company's board of directors authorizes the company's management and its authorized personnel to handle specific matters.
According to the company's "Prospectus", the implementation entity of the fundraising project "Kaipule Public Health Medical Materials Industrial Park Construction Project" is Kaiple. In order to further improve the efficiency of the use of raised funds, promote the implementation progress of fundraising projects, and better protect the legitimate rights and interests of investors, in accordance with the "Measures for the Continuous Supervision of Listed Companies of the Beijing Stock Exchange (Trial)", the "Stock Listing Rules of the Beijing Stock Exchange" and the "Guidelines for the Continuous Supervision of Listed Companies of the Beijing Stock Exchange No. 9" - "Management of Raised Funds" and other relevant laws, regulations and normative documents, as well as the relevant requirements of the company's "Raised Funds Management System"; Kepler has opened a special account for raised funds at the Suzhou Lumu Branch of Industrial and Commercial Bank of China Co., Ltd. and signed a fund supervision agreement to supervise the storage and use of borrowed funds.
4. Basic information about the loan recipients
Company Name: Anhui Kaiple Medical Technology Co., Ltd.
Unified social credit code: 91341800MA2W5U8C82
Date of establishment: September 3, 2020
Registered address: No. 11, Yuhe Road, Xuancheng Economic and Technological Development Zone, Anhui Province
Legal representative: Zhang Yong
Registered capital: RMB 100 million
Enterprise type: Limited liability company (a sole proprietorship of a legal person that is not invested or controlled by a natural person)
Business scope: Licensed projects: production of Class III medical devices; production of Class II medical devices; operation of Class III medical devices; production of protective equipment for medical staff (Class II medical devices); production of sanitary products and disposable medical supplies (projects that are subject to approval according to law can only be carried out after approval by relevant departments. Specific business projects are subject to approval documents or licenses from relevant departments). General projects: import and export of goods; import and export of technology; import and export agency; technical services, technology development, technical consultation, and technical exchanges , technology transfer, technology promotion; production of Class I medical devices; sales of Class I medical devices; sales of Class II medical devices; production of protective equipment for medical staff (Class I medical equipment); wholesale of protective equipment for medical staff; engineering and technology research and experimental development; medical research and experimental development; wholesale of pet food and supplies; retail of pet food and supplies; sales of personal hygiene products; sales of sanitary products and disposable medical supplies (except for licensed businesses, items that are not prohibited or restricted by laws and regulations can be independently operated in accordance with the law)
Equity structure: The company holds 100% equity of Kepler.
5. The purpose of this loan, its impact on the company and follow-up arrangements
The company's use of the raised funds to provide loans to Kepler this time is based on the construction needs of the raised investment project and is in line with the use plan of the raised funds. There is no change or disguised change in the use of the raised funds. The use and purpose of raised funds are in line with the company's development strategy and relevant laws and regulations, and are in line with the interests of the company and all shareholders.
In accordance with relevant regulations such as the "Measures for the Continuous Supervision of Listed Companies on the Beijing Stock Exchange (Trial)", the Beijing Stock Exchange Stock Listing Rules, and the relevant requirements of the "Raised Funds Management System" formulated by the company, the company and its subsidiaries Kepler, Soochow Securities, and the commercial bank where the raised funds are deposited signed a raised funds supervision agreement to implement effective supervision over the use of raised funds and ensure that the funds are used exclusively.
6. Implementation review procedures and related opinions
(1) Deliberation opinions of the Audit Committee
On March 27, 2026, the company held the 15th meeting of the Audit Committee of the second board of directors, reviewed and approved the "Proposal on Using Part of the Raised Funds to Provide Loans to Wholly-Owned Subsidiaries to Implement Fund-raising Projects", and agreed that the company would use part of the raised funds to provide loans to Kepler to implement fund-raising projects, and agreed to submit the proposal to the company's board of directors for review.
(2) Review opinions of the board of directors
On March 27, 2026, the company held the 19th meeting of the second board of directors, and reviewed and approved the "Proposal on Using Part of the Raised Funds to Provide Loans to Wholly-Owned Subsidiaries to Implement Fund-raising Projects", and agreed that the company would use part of the raised funds to provide loans to Kepler to implement fund-raising projects. The proposal is within the scope of the board of directors' approval authority and does not need to be submitted to the company's shareholders' meeting for review.
7. Review Opinions of the Sponsor
After verification, the sponsoring agency believes that the company's use of part of the raised funds to borrow money from its wholly-owned subsidiary Kepler to implement the investment project has been reviewed and approved at the 15th meeting of the Audit Committee of the second session of the board of directors and the 19th meeting of the second session of the board of directors. This matter is within the scope of the board of directors' deliberation authority and does not need to be submitted to the company's shareholders' meeting for review. This matter complies with the requirements of relevant laws and regulations such as the "Beijing Stock Exchange's Securities Issuance and Listing Sponsorship Business Management Rules", "Beijing Stock Exchange's Stock Listing Rules", "Beijing Stock Exchange's Continuous Supervision Measures for Listed Companies (Trial)" and other relevant laws and regulations. It complies with the purpose of the raised funds disclosed in the "Prospectus" and is in the interests of the company and all shareholders. It will not have an adverse impact on the company's normal production, operation and business development, and will not harm the interests of shareholders.
In summary, the sponsor has no objection to the company using part of the raised funds to borrow money from subsidiaries to implement the investment projects.
8. Documents for reference
"Resolution of the 19th Meeting of the Second Board of Directors of Jiangsu Aishelun Medical Technology Group Co., Ltd." "Resolution of the 15th Meeting of the Audit Committee of the Second Board of Directors of Jiangsu Aishelun Medical Technology Group Co., Ltd."
Board of Directors of Jiangsu Aishelun Medical Technology Group Co., Ltd.
March 27, 2026